ArticleThe Journal of infectious diseases2012
Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis.
Article in The Journal of infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02640807 (A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7), which is not on this map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients.
Who cites it
80 citing papers in PubMed, 130 citations in OpenAlex.
- Dose Optimization of rhIL-7-hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor-Mediated Recycling-Based and Target-Mediated Drug Disposition Pharmacokinetic Model.Clinical and translational science · 2025Trial
- The perioperative dynamics of IL-7 following robot-assisted and open colorectal surgery.Scientific reports · 2018Trial
- Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.JCI insight · 2018Trial
- N-terminal pro-C-natriuretic peptide and cytokine kinetics in dogs with endotoxemia.Journal of veterinary internal medicineTrial
- The immunology of sepsis: translating new insights into clinical practice.Nature reviews. Nephrology · 2026Review
- Analysis of the association of neutrophil-to-lymphocyte ratio, MPV-to-platelet ratio, and clinical risk factors for mortality in ICU patients with candidemia: a 10-year retrospective analysis.BMC infectious diseases · 2025Observational
- Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD-1 Inhibition as Potential Treatment Option.Mycoses · 2025Observational
- Endogenous IL-7 Variation in Relation to Lymphocyte Subtypes in Septic Patients.Medicina (Kaunas, Lithuania) · 2025Observational
- Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).Journal of inflammation research · 2025Review
- The immunosuppressive mechanisms induced by sepsis and the corresponding treatment strategies.Frontiers in immunology · 2025Review
- Potential of interleukin-7 in sepsis as a biomarker and therapeutic agent: a narrative review.Frontiers in medicine · 2025Review
- Dynamic functional assessment of T cells reveals an early suppression correlating with adverse outcome in polytraumatized patients.Frontiers in immunology · 2025Article
- Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- Adjunctive immunotherapeutic agents in patients with sepsis and septic shock: a multidisciplinary consensus of 23.Journal of anesthesia, analgesia and critical care · 2024Article
- Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities.British journal of anaesthesia · 2024Review
- The effect of adoptive transferring myeloid-derived suppressor cells in ventilator-induced lung injury mice.Heliyon · 2024Article
- Exploring the role of antioxidants in sepsis-associated oxidative stress: a comprehensive review.Frontiers in cellular and infection microbiology · 2024Review
- Immune dysregulation in sepsis: experiences, lessons and perspectives.Cell death discovery · 2023Review
- Immune Adjuvant Therapy With Interleukin-7 in a Lymphopenic Patient With Aplastic Anemia and Mucormycosis.Critical care explorations · 2023Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundSecondary hospital-acquired fungal infections are common in critically-ill patients and mortality remains high despite antimicrobial therapy. Interleukin-7 (IL-7) is a potent immunotherapeutic agent that improves host immunity and has shown efficacy in bacterial and viral models of infection. This study examined the ability of IL-7, which is currently in multiple clinical trials (including hepatitis and human immunodeficiency virus), to improve survival in a clinically relevant 2-hit model of fungal sepsis.
methodsMice underwent cecal ligation and puncture to induce peritonitis. Four days later, surviving mice had intravenous injection with Candida albicans. Following Candida infection, mice were treated with IL-7 or saline control. The effect of IL-7 on host immunity and survival was recorded.
resultsIL-7 ameliorated the loss of immune effector cells and increased lymphocyte functions, including activation, proliferation, expression of adhesion molecules, and interferon-γ production. These beneficial effects of IL-7 were associated with an increase in global immunity as reflected by an enhanced delayed type hypersensitivity response and a 1.7-fold improvement in survival.
conclusionsThe present findings showing that IL-7 improves survival in fungal sepsis, together with its previously reported efficacy in bacterial and viral infectious models, further supports its use as a novel immunotherapeutic in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.